<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483115</url>
  </required_header>
  <id_info>
    <org_study_id>TPN171H-P201</org_study_id>
    <nct_id>NCT04483115</nct_id>
  </id_info>
  <brief_title>Acute Haemodynamic Study of TPN171H in Patients With Pulmonary Arterial Hypertension</brief_title>
  <official_title>Multi-center, Randomized，Placebo and Positive Controlled Clinical Study of TPN171H Tablets on Acute Haemodynamics in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vigonvita Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Institute of Materia Medica, Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vigonvita Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose
      TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial
      hypertension.The trial is expected to include 60 patients, divided into 6 groups, according
      to 1:1:1:1:1:1 into the placebo group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil
      tablets 20mg, 40mg group, each group 10 cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, randomized, placebo and positive controlled phase IIa
      proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute
      hemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected
      to include 60 patients, divided into 6 groups, according to 1:1:1:1:1:1 into the placebo
      group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil tablets 20mg, 40mg group, each
      group 10 cases. During the screening period, the tube placement period, and the observation
      period, the patients will conduct various inspections and evaluation observations as
      required.

      The Swan-Ganz floating catheter and echocardiography were used to evaluate the efficacy of
      TPN171H; PK parameters: including Tmax, Cmax, AUC0-t , t1/2,CL/F, Vz/F, λz; Safety evaluation
      indicators include: vital signs, physical examination, laboratory examination (blood routine,
      blood biochemistry, blood gas analysis), 12-lead ECG, adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of the maximum change in pulmonary vascular resistance(PVR) to the second baseline</measure>
    <time_frame>Within 24 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum change in PVR</measure>
    <time_frame>Within 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve for reduction in PVR</measure>
    <time_frame>Within 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arterial oxygenation</measure>
    <time_frame>Within 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in right ventricular function</measure>
    <time_frame>Within 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>TPN171H 2.5mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPN171H 2.5mg tablet + Placebo 10mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPN171H 5mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPN171H 5mg tablet + Placebo 10mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPN171H 10mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPN171H 10mg tablet + Placebo 5mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 5mg tablet+ Placebo 10mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tadalafil 20mg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tadalafil tablet 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tadalafil 40mg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tadalafil tablets 20mg *2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPN171H</intervention_name>
    <description>Tablets; Oral; Single dose</description>
    <arm_group_label>TPN171H 10mg group</arm_group_label>
    <arm_group_label>TPN171H 2.5mg group</arm_group_label>
    <arm_group_label>TPN171H 5mg group</arm_group_label>
    <other_name>Simmerafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets; Oral; Single dose</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Tablets; Oral; Single dose</description>
    <arm_group_label>tadalafil 20mg group</arm_group_label>
    <arm_group_label>tadalafil 40mg group</arm_group_label>
    <other_name>ADCIRCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 to 75;

          -  Patients who have voluntarily decided to participate in this study, and signed the
             informed consent form;

          -  Patients who are able to understand and follow study plans and instructions;

          -  Patients with symtomatic PAH (Group1), a pulmonary vascular resistance (PVR) &gt; 3 Wood,
             a mean pulmonary artery pressure (mPVP) ≥25 mmHg and a pulmonary artery wedge pressure
             (PAWP) ≤ 15 mmHg either due to:

               1. Idiopathic PAH (IPAH)

               2. Familial PAH

               3. Associated PAH due to drugs or toxins

               4. Associated PAH due to connective tissue disease

               5. Associated PAH due to congenital heart disease, if patients underwent surgical
                  correction more than 1 year prior to screening

          -  Have a current diagnosis of being in WHO functional class II or III;

          -  Patients who are willing to take proper contraceptive during the study and within 3
             months after the study completed.

        Exclusion Criteria:

          -  All types of PH except subtypes of Group1 specified in the inclusion criteria;

          -  Moderate to severe COPD (FEV1 &lt; 60% predicted);

          -  Moderate to severe restrictive lung disease (FVC &lt; 70% predicted);

          -  Pre-treatment with PAH therapy within the last 3 months before the screening visit
             (including endothelin receptor antagonists, PDE5 inhibitors, guanylate cyclase agonist
             and prostacycline analogues);

          -  A &quot;positive&quot; response to acute vasodilator testing;

          -  Coagulation dysfunction (defined as activated partial thromboplastin time and
             international normalized ratio are both &gt;1.5 times upper limit normal) or patients
             with potential bleeding risk;

          -  Hepatic dysfunction indicated by: serum bilirubin＞1.5 times upper limit normal, ALT
             and AST＞2.5 times upper limit normal;

          -  Renal insufficiency (creatinine clearance＜30 mL/min)；

          -  Systolic blood pressure＜90 mmHg at screening;

          -  QT prolongation at screening, whose values (QTcF) exceeding 450 msec in males and 470
             msec in females;

          -  Have enrolled in/or have a plan of an exercise training program for pulmonary
             rehabilitation before the screening visit/or during the study;

          -  Patients who have a recent (within 3 months) history of abusing alcohol or illicit
             drugs;

          -  Body weight＜40 kg；

          -  Patients who have participated in a clinical study involving another investigational
             drug within 1 month before the screening visit;

          -  For any other reasons that affect compliance with the study protocol, especially the
             long-term monitoring of floating catheters, according to the decision of
             investigators;

          -  HBV, HCV, HIV or Tp infection;

          -  Patients with gastrointestinal, urinary, reproductive, immunologic, endocrine, or
             central nervous system disease that, in the opinion of the investigator, will affect
             the study;

          -  Have a history of malignancies within 2 years, except for a cured basal cell or skin
             squamous cell carcinoma;

          -  Pregnant women, or breast feeding women;

          -  Patients with hypersensitivity to iloprost or any of the excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Huo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huaqing Duan</last_name>
    <phone>+86-18061926005</phone>
    <email>huaqing.duan@vigonvita.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhicheng Jing</last_name>
      <email>jingzhicheng@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yong Huo</last_name>
      <email>huoyong@263.net.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiang Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lan Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>Acute Haemodynamic Study</keyword>
  <keyword>PK/PD study</keyword>
  <keyword>TPN171H</keyword>
  <keyword>Simmerafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

